Health‐associated reference values for arginine, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) measured with high‐performance liquid chromatography
Authors:
- 1 January 2007
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 67 (8) , 868-876
Abstract
Objective. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide production. It has been implicated in various pathological processes, especially processes involving the cardiovascular system. Plasma concentration of ADMA (p‐ADMA) has been measured in several studies with different techniques, and a wide range of normal values has been published. With use of high performance liquid chromatography (HPLC) with fluorescence detection, we have established health‐associated reference values for p‐ADMA, p‐arginine, p‐SDMA and the p‐arginine/p‐ADMA and p‐arginine/p‐SDMA ratios. Material and methods. Blood samples were taken from 238 blood donors (112 F and 126 M). HPLC was used to analyse arginine, ADMA and SDMA. Reference values are presented as 2.5 and 97.5 percentiles estimated by the bootstrap method. Results. The reference interval for p‐ADMA is 0.40–0.77 µmol/L for the whole population, 0.41–0.79 µmol/L for men, 0.38–0.73 µmol/L for women 45 years or less, and 0.41–0.84 µmol/L for women >45 years. Conclusions. Age affects p‐ADMA in healthy women, but not in men.Keywords
This publication has 27 references indexed in Scilit:
- Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: Results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) studyAmerican Heart Journal, 2006
- The DDAH-ADMA-NOS PathwayTherapeutic Drug Monitoring, 2005
- Asymmetrical Dimethylarginine Predicts Progression to Dialysis and Death in Patients with Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2005
- ADMA metabolism and clearanceVascular Medicine, 2005
- DDAH gene and cardiovascular riskVascular Medicine, 2005
- Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective studyThe Lancet, 2001
- Asymmetric Dimethylarginine Plasma Concentrations Differ in Patients with End-Stage Renal DiseaseJournal of the American Society of Nephrology, 1999
- Protein methylationCurrent Opinion in Cell Biology, 1993
- Endogenous Dimethylarginine as an Inhibitor of Nitric Oxide SynthesisJournal of Cardiovascular Pharmacology, 1992
- Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failureThe Lancet, 1992